Patient-Derived Xenograft models have been reported to more accurately reflect the patient tumors from which they were derived in terms of morphology, tissue architecture, and mutational stability. PDX models are now considered to provide a superior experimental model system of pre-clinical drug responses. Read this article which describes the generation of a PDX biobank from stage I-IV chemotherapy-naive CRC tumors.
Read more: A Biobank of Colorectal Cancer Patient-Derived Xenografts - OpenSpecimen